Filip Fratev / Micar21
Filip Fratev, Micar21, Denisse A. Gutierrez Renato J. Aguilera suman sirimulla
Publication Date (Web): April 20, 2018
Copyright © 2019 J.Med Chem
AKT1 is emerging as a useful target for treating cancer. Herein, we discovered a new set of ligands that inhibit the AKT1, as shown by in vitro binding and cell line studies, using a newly designed virtual screening protocol that combines structure-based pharmacophore and docking screens. Taking together with the biological data, the combination of structure based pharamcophore and docking methods demonstrated reasonable success rate in identifying new inhibitors (60-70%) proving the success of aforementioned approach. A detail analysis of the ligand-protein interactions was performed explaining observed activities.